Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells 1,890 Shares of Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $44.57, for a total value of $84,237.30. Following the completion of the sale, the director owned 3,559,765 shares of the company’s stock, valued at $158,658,726.05. The trade was a 0.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Orbimed Advisors Llc also recently made the following trade(s):

• On Tuesday, February 3rd, Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.58, for a total value of $1,295,628.54.
• On Wednesday, December 24th, Orbimed Advisors Llc sold 33,356 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.55, for a total transaction of $1,486,009.80.
• On Friday, December 19th, Orbimed Advisors Llc sold 875 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total value of $38,928.75.
• On Thursday, December 18th, Orbimed Advisors Llc sold 100 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.49, for a total value of $4,449.00.
• On Wednesday, December 17th, Orbimed Advisors Llc sold 900 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.50, for a total value of $40,050.00.
• On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total value of $71,184.00.
• On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.60, for a total transaction of $530,294.00.
• On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.54, for a total transaction of $4,212,726.82.

Sionna Therapeutics Stock Down 7.1%

SION stock traded down $3.17 during trading on Wednesday, hitting $41.31. The company had a trading volume of 313,154 shares, compared to its average volume of 306,528. The firm has a market capitalization of $1.84 billion and a P/E ratio of -8.48. The company has a 50 day simple moving average of $41.45 and a 200-day simple moving average of $32.74. Sionna Therapeutics, Inc. has a 52-week low of $7.26 and a 52-week high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Raymond James Financial reissued a “strong-buy” rating and issued a $53.00 price target on shares of Sionna Therapeutics in a report on Monday, January 5th. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. BTIG Research reaffirmed a “buy” rating and set a $58.00 price objective on shares of Sionna Therapeutics in a research note on Wednesday, January 14th. Royal Bank Of Canada reaffirmed an “underperform” rating and issued a $24.00 target price on shares of Sionna Therapeutics in a research note on Monday, December 1st. Finally, Lifesci Capital initiated coverage on Sionna Therapeutics in a report on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $45.43.

Institutional Trading of Sionna Therapeutics

Institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new stake in shares of Sionna Therapeutics during the 4th quarter worth approximately $36,000. Russell Investments Group Ltd. purchased a new stake in shares of Sionna Therapeutics during the third quarter worth about $30,000. BNP Paribas Financial Markets purchased a new position in shares of Sionna Therapeutics during the 2nd quarter worth $31,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Sionna Therapeutics during the fourth quarter worth about $89,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Sionna Therapeutics in the second quarter worth approximately $45,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.